Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).
Andreas Du Bois
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Anne Floquet
No relevant relationships to disclose
Jae Weon Kim
No relevant relationships to disclose
Jörn Rau
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Michael Friedlander
No relevant relationships to disclose
Sandro Pignata
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Keiichi Fujiwara
Honoraria - GlaxoSmithKline
Ignace Vergote
Consultant or Advisory Role - GlaxoSmithKline
Nicoletta Colombo
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Mansoor Raza Mirza
No relevant relationships to disclose
Bradley J. Monk
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Pauline Wimberger
No relevant relationships to disclose
Isabelle Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar; Roche
Rongyu Zang
No relevant relationships to disclose
Ivan Diaz-Padilla
No relevant relationships to disclose
Klaus H. Baumann
No relevant relationships to disclose
Jae Hoon Kim
No relevant relationships to disclose
Philipp Harter
No relevant relationships to disclose